Targeting HER2-positive breast cancer: advances and future directions
SM Swain, M Shastry, E Hamilton - Nature reviews Drug discovery, 2023 - nature.com
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …
[HTML][HTML] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast …
HJ Burstein, G Curigliano, B Thürlimann, WP Weber… - Annals of oncology, 2021 - Elsevier
The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆
Metastatic breast cancer (MBC) is an incurable disease, but survival improvements have
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …
been reported with appropriate therapeutic strategies. 1-8 Systemic therapy is the standard …
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open …
Background In the single-arm, phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan
showed robust activity in patients with HER2-positive metastatic breast cancer who were …
showed robust activity in patients with HER2-positive metastatic breast cancer who were …
[HTML][HTML] EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
Highlights•This Clinical Practice Guideline provides management recommendations for
patients with brain metastases from solid tumours.•The guideline covers clinical and …
patients with brain metastases from solid tumours.•The guideline covers clinical and …
Breast cancer: an up‐to‐date review and future perspectives
R Hong, B Xu - Cancer communications, 2022 - Wiley Online Library
Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …
associated with many risk factors, including genetic and hereditary predisposition. Breast …
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
The development of anti-HER2 agents has been one of the most meaningful advancements
in the management of metastatic breast cancer, significantly improving survival outcomes …
in the management of metastatic breast cancer, significantly improving survival outcomes …
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–
25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the …
25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the …
[HTML][HTML] Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain …
Background In the primary analysis of the HER2CLIMB trial, tucatinib added to trastuzumab
and capecitabine significantly improved overall survival (OS) and progression-free survival …
and capecitabine significantly improved overall survival (OS) and progression-free survival …
Systemic therapy for advanced human epidermal growth factor receptor 2–positive breast cancer: ASCO guideline update
SH Giordano, MAB Franzoi, S Temin… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To update evidence-based guideline recommendations to practicing oncologists
and others on systemic therapy for patients with human epidermal growth factor receptor 2 …
and others on systemic therapy for patients with human epidermal growth factor receptor 2 …